Related Experiment Video
Updated: Aug 23, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Dysfunctional microglia and tau pathology in Alzheimer's disease
1Department of Cytology, Embryology and Histology, Azerbaijan Medical University, S. Vurgun Street, Baku 1102, Azerbaijan.
Abstract:
Extensive human studies and animal models show that chronic immune system stimulation involving microglia, inflammasome, complement activation, synthesis of cytokines, and reactive oxygen species exacerbates neurodegeneration in Alzheimer's disease (AD) and other tauopathies. Abnormalities in tau, Aβ, and microglial activation are frequently observed in dementia patients and indicate that these elements may work in concert to cause cognitive impairment. Contradicting reports from postmortem studies demonstrating the presence of Aβ aggregates in the brains of cognitively healthy individuals, as well as other investigations, show that tau aggregation is more strongly associated with synapse loss, neurodegeneration, and cognitive decline than amyloid pathology. Tau association with microtubules' surface promotes their growth and maintains their assembly, dynamicity, and stability. In contrast, the reduced affinity of hyperphosphorylated and mislocalized tau to microtubules leads to axonal deficits and neurofibrillary tangles (NFTs). Loss of microglial neuroprotective and phagocytic functions, as indicated by the faulty clearance of amyloid plaques, as well as correlations between microglial activation and tau tangle spread, all demonstrate the critical involvement of malfunctioning microglia in driving tau propagation. This review discusses the recent reports on the contribution of microglial cells to the development and progression of tau pathology. The detailed study of pathogenic mechanisms involved in interactions between neuroinflammation and tau spread is critical in identifying the targets for efficacious treatment strategies in AD.
Insights
Chronic immune stimulation and malfunctioning microglia worsen neurodegeneration in Alzheimer's disease (AD) and tauopathies. Microglial dysfunction drives tau pathology spread, highlighting targets for AD treatments.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Chronic immune stimulation, involving microglia and inflammasome activation, exacerbates neurodegeneration in Alzheimer's disease (AD) and tauopathies.
- Abnormalities in tau, amyloid-beta (Aβ), and microglial activation are hallmarks of dementia, suggesting their concerted role in cognitive impairment.
- While Aβ aggregates are found in healthy individuals, tau pathology correlates more strongly with neurodegeneration and cognitive decline.
Purpose of the Study:
- To review recent findings on the role of microglial cells in the development and progression of tau pathology.
- To discuss the pathogenic mechanisms linking neuroinflammation and tau spread.
- To identify potential therapeutic targets for AD based on these interactions.
Main Methods:
- Literature review of human studies and animal models.
- Analysis of postmortem brain studies and investigations on tau and amyloid pathology.
- Examination of microglial functions, including phagocytosis and neuroprotection.
Main Results:
- Malfunctioning microglia exhibit impaired clearance of amyloid plaques and correlate with tau tangle spread.
- Hyperphosphorylated tau detaches from microtubules, leading to axonal deficits and neurofibrillary tangles (NFTs).
- Microglial dysfunction is critical in driving tau pathology propagation.
Conclusions:
- Microglial cells play a critical role in the pathogenesis and spread of tau pathology in AD and other tauopathies.
- Understanding the interplay between neuroinflammation and tau spread is crucial for developing effective AD treatments.
- Targeting microglial pathways offers a promising therapeutic strategy for tauopathies.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Alzheimer's Disease: Treatment

